$VBIO

Valion Bio, Inc. (VBIO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Valion Bio Advancing Entolimod into U.S. Government-Funded Therapeutic Efficacy Study Following Positive Safety Results NIAID-RNCP elects to evaluate the efficacy of Entolimod on gastrointestinal acute radiation syndrome (“GI-ARS”), after the announcement of positive

Valion Bio reported positive safety results for Entolimod in a preclinical study, with no treatment-related toxicity or significant body-weight differences in mice. AFRRI plans a fully funded efficacy study to assess survival and gastrointestinal recovery post-radiation. According to the company, the study will be fully funded.

Valion Bio, Inc. (VBIO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Valion Bio Announces Positive Safety Results from U.S. Government-Funded Entolimod Study, Paving Way for Therapeutic Efficacy Evaluation AFRRI study found no evidence of treatment-related toxicity following a single dose of Entolimod, supporting advancement toward a

Valion Bio (VBIO) raised $4.77M in Series B and C financing. The Series B deal with 3i was $50K, while Series C brought in $4.72M, including $1.5M cash and $3.22M for overdue payments. Both agreements were signed on October 26, 2026.

Valion Bio, Inc. (VBIO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Series B Closing Valion Bio, Inc., a Delaware corporation (the “Company”), and 3i, LP (“3i”) are party to that certain Securities Purchase Agreement, dated as of April 29, 2025 (as assigned and amended as of December 9, 2025,

Valion Bio (VBIO) is considering strategic options, including a potential sale of its subsidiary Velocity Bioworks, after receiving unsolicited acquisition inquiries. The company has hired an investment bank to advise on the process, prioritizing retaining production rights for Entolimod. No deal has been finalized, and Valion will evaluate proposed terms and valuation.

Valion Bio, Inc. (VBIO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Valion Bio Receives Unsolicited Acquisition Interest in Velocity Bioworks; Weighs Strategic Options Unsolicited Interest Reinforces Velocity's Strategic Value as Valion Bio Evaluates Opportunities to Advance Entolimod SAN ANTONIO, TX / October 26, 2026 / ACCESS Newsw

Valion Bio, Inc. (VBIO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Valion Bio ’ s New Leadership Unveils 30-Day Agenda to Accelerate Clinical Pipeline and Unlock Shareholder Value Interim CEO Dean Zikria ’ s initial review prioritizes Entolimod and pipeline advancement, commercialization of Velocity Bioworks, and strategic opportuni

Valion Bio Inc. (VBIO) interim CEO Dean Zikria outlined strategic priorities, focusing on advancing Entolimod and other pipeline assets, pursuing revenue opportunities for Velocity Bioworks, and evaluating strategic partnerships. Entolimod, the lead drug candidate, has received $35.6 million in non-dilutive funding and holds FDA designations. The company is also developing Entolasta and an oral mucosal formulation. Velocity Bioworks is being evaluated for potential partnerships or a sale.

Valion Bio announced that Velocity Bioworks completed an initial feasibility evaluation of LarmorBio’s BioScan-NMR, showing NMR signals correlate with OD600. The results support further development of the platform, which aims to enable real-time, non-invasive monitoring of microbial growth. Valion Bio (VBIO) filed the update with the SEC.